Orforglipron (LY3502970) is an investigational oral GLP-1 receptor agonist developed by Eli Lilly, currently undergoing clinical trials for the treatment of type 2 diabetes and obesity. While it offers the convenience of a daily pill, it’s important to be aware of potential side effects.


⚠️ Common Side Effects

The most frequently reported side effects of orforglipron are gastrointestinal in nature:

These side effects are generally mild to moderate and often occur during the dose escalation period. They typically subside as the body adjusts to the medication. (Lilly Investor Relations)


⚠️ Less Common Side Effects

In some cases, participants have reported:

These side effects are less common and may vary among individuals.


⚠️ Rare and Serious Side Effects

Serious side effects are rare but can include:

It’s important to note that no deaths or fatal serious adverse events have been reported in clinical trials. (Wiley Online Library)


🧭 Summary

Orforglipron has shown promising results in clinical trials, with participants experiencing significant weight loss and improved blood sugar levels. While the most common side effects are gastrointestinal and generally mild to moderate, it’s essential to consult with a healthcare provider before starting any new medication. They can provide personalized advice and monitor for any potential side effects.

If you have any more questions or need further information, feel free to ask!

Leave a Reply

Your email address will not be published. Required fields are marked *